Skip to main content

Advertisement

SpringerLink
Log in

Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients

Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Leptomeningeal metastasis (LM) is a devastating complication of solid tumors. A retrospective study was carried out to evaluate the outcome and prognostic factors of LM. Patients with LM were identified through MRI from January 2008 to August 2011. 46 patients were included. 32 had NSCLC, five had breast cancer and nine had other cancers. Treatment included radiotherapy in 49 %, intrathecal chemotherapy in 12 %, and systemic chemotherapy in 61 % of the patients. The median survival was 4.4 (range, 0–45) months. KPS score, radiotherapy and systemic treatment were significantly associated with survival. Eighteen (58 %) of NSCLC patients received EGFR-TKI therapy, with a median survival of 13 months. EGFR-TKI therapy was identified as an independent prognostic factor for survival in the NSCLC subgroup. The prognosis remains poor in patients with LM from solid tumors. KPS ≥70, systemic treatment and radiotherapy represent positive prognostic factors. EGFR-TKI therapy improves outcomes of LM in selected NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Chamberlain MC (2010) Leptomeningeal metastasis. Semin Neurol 30:236–244

    Article  PubMed  Google Scholar 

  2. Taillibert S, Laigle-Donadey F, Chodkiewicz C et al (2005) Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75:85–99

    Article  PubMed  Google Scholar 

  3. Kaplan JG, DeSouza TG, Farkash A et al (1990) Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9:225–229

    Article  CAS  PubMed  Google Scholar 

  4. Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375

    Article  CAS  PubMed  Google Scholar 

  5. Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772

    Article  CAS  PubMed  Google Scholar 

  6. Straathof CS, de Bruin HG, Dippel DW et al (1999) The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 246:810–814

    Article  CAS  PubMed  Google Scholar 

  7. Singh SK, Leeds NE, Ginsberg LE (2002) MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol 23:817–821

    PubMed  Google Scholar 

  8. Clarke JL, Perez HR, Jacks LM et al (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449–1454

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Herrlinger U, Forschler H, Kuker W et al (2004) Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 223:167–178

    Article  PubMed  Google Scholar 

  10. Oechsle K, Lange-Brock V, Kruell A et al (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 136:1729–1735

    Article  PubMed  Google Scholar 

  11. Waki F, Ando M, Takashima A et al (2009) Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 93:205–212

    Article  PubMed  Google Scholar 

  12. Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80–84

    Article  PubMed  Google Scholar 

  13. Umemura S, Tsubouchi K, Yoshioka H et al (2012) Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: okayama Lung Cancer Study Group. Lung Cancer 77:134–139

    Article  PubMed  Google Scholar 

  14. Oliveira M, Braga S, Passos-Coelho JL et al (2011) Complete response in HER2 + leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 127:841–844

    Article  CAS  PubMed  Google Scholar 

  15. Fukuhara T, Saijo Y, Sakakibara T et al (2008) Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 214:359–363

    Article  CAS  PubMed  Google Scholar 

  16. Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16:88–92

    Article  PubMed  Google Scholar 

  17. Chamberlain MC (1998) Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37:271–284

    Article  CAS  PubMed  Google Scholar 

  18. Groves MD (2010) New strategies in the management of leptomeningeal metastases. Arch Neurol 67:305–312

    Article  PubMed  Google Scholar 

  19. Morris PG, Reiner AS, Szenberg OR et al (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7:382–385

    Article  PubMed  Google Scholar 

  20. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Schäfer N, Scheffler B, Stuplich M et al (2013) Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 31:e173–e174

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China

    Chunxia Du, Ruoxi Hong, Yuankai Shi & Jinwan Wang

  2. Department of Radiology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China

    Xiaoduo Yu

Authors
  1. Chunxia Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruoxi Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuankai Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoduo Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jinwan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinwan Wang.

Additional information

Chunxia Du and Ruoxi Hong contribute equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Du, C., Hong, R., Shi, Y. et al. Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. J Neurooncol 115, 285–291 (2013). https://doi.org/10.1007/s11060-013-1228-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1228-x

Keywords

Search

Navigation